Artelo Biosciences Partners with ABK Labs for Strategic Growth

Artelo Biosciences ( (ARTL) ) has issued an announcement.

On August 1, 2025, Artelo Biosciences, Inc. entered into a four-year Consulting Agreement with ABK Labs, Inc. to provide strategic advisory services for the company’s digital asset strategy and other business development areas. As part of the agreement, Artelo will issue warrants to ABK Labs to purchase up to 55,000 shares of its common stock, contingent upon performance milestones and continued service. This partnership aims to enhance Artelo’s market position and operational capabilities, potentially impacting its market capitalization and stakeholder value.

The most recent analyst rating on (ARTL) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.

Spark’s Take on ARTL Stock

According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.

Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.

To see Spark’s full report on ARTL stock, click here.

More about Artelo Biosciences

Artelo Biosciences, Inc. operates in the biotechnology industry, focusing on the development of novel therapeutics aimed at treating cancer, pain, and inflammation. The company is engaged in advancing its proprietary platform of small molecule therapeutics and is committed to addressing unmet medical needs in these areas.

Average Trading Volume: 669,836

Technical Sentiment Signal: Hold

Current Market Cap: $6.68M

For detailed information about ARTL stock, go to TipRanks’ Stock Analysis page.